Volume 4.45 | Nov 15

Mammary Cell News 4.45 November 15, 2012
Mammary Cell News
     In this issue: Publications | Reviews Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Mammary Cell News on Twitter
RhoB Differentially Controls Akt Function in Tumor Cells and Stromal Endothelial Cells during Breast Tumorigenesis
Investigators demonstrated in established murine and human models of breast cancer how differential regulation of Akt by the small GTPase RhoB in cancer cells or stromal endothelial cells determines their dormancy versus outgrowth when angiogenesis becomes critical. [Cancer Res] Abstract

Air-Liquid Interface Culture for Respiratory Research: Watch Q&A Video
PUBLICATIONS (Ranked by impact factor of the journal)


An Integrated Genomic Screen Identifies LDHB as an Essential Gene for Triple-Negative Breast Cancer
Scientists used integrative genomic analysis to identify candidate oncogenes in triple-negative breast tumors and assess their function through loss of function screening. They identified lactate dehydrogenase B (LDHB), a component of glycolytic metabolism, as an essential gene in triple-negative breast cancer. [Cancer Res] Abstract

Simultaneous Inhibition of Metastasis and Growth of Breast Cancer by Co-Delivery of Twist shRNA and Paclitaxel Using Pluronic P85-PEI/TPGS Complex Nanoparticles
An attempt to simultaneously inhibit the metastasis and growth of tumor by co-delivering Twist shRNA and paclitaxel using the conjugate of pluronic P85 (P85) and low molecular weight polyethyleneimine (PEI)/D-a-tocopheryl polyethylene glycol 1000 succinate (TPGS) complex nanoparticles was performed on metastatic 4T1 breast cancer cell line and its pulmonary metastasis mice model. [Biomaterials] Abstract

Flotillin-2 Deficiency Leads to Reduced Lung Metastases in a Mouse Breast Cancer Model
Investigators identified flotillin-2 as highly amplified in a high-throughput comparative genomic hybridization screen of human breast cancer cell lines and breast tumor samples. Short hairpin RNA-mediated reduction of flotillin-2 protein levels significantly reduced the tumorigenicity and metastatic capability of a human breast cancer cell line in vivo. [Oncogene] Abstract

Prospective Dual Role of Mesenchymal Stem Cells in Breast Tumor Microenvironment
Researchers found that a distinct subset of breast resident, adipose tissue-derived mesenchymal stem cells display a strong affinity for conditioned media from two breast cancer cell lines, MDA-MB 231 and MCF-7. [Breast Cancer Res Treat] Abstract

Embryonic Morphogen Nodal Promotes Breast Cancer Growth and Progression
Scientists demonstrated that the human embryonic stem cell-associated factor Nodal promotes breast cancer growth. [PLoS One] Full Article

Py2T Murine Breast Cancer Cells, a Versatile Model of TGFβ-Induced EMT In Vitro and In Vivo
Researchers sought to generate a transplantable cellular model system that allows defined experimental manipulation and analysis of epithelial to mesenchymal transition (EMT) in vitro and at the same time recapitulates oncogenic EMT in vivo. [PLoS One] Full Article

Curcuminoids Block Transforming Growth Factor-β Signaling in Human Breast Cancer Cells and Limit Osteolysis in a Murine Model of Breast Cancer Bone Metastasis
Effects of curcuminoids on breast cancer cell secretion of the bone-resorptive peptide parathyroid hormone-related protein and on lytic breast cancer bone metastasis were evaluated. [J Nat Prod] Abstract


A Multicenter, Phase I, Dose-Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of Etirinotecan Pegol in Patients with Refractory Solid Tumors
This study was designed to establish the maximum-tolerated dose and to evaluate tolerability, pharmacokinetics, and antitumor activity of etirinotecan pegol. [Clin Cancer Res] Abstract

Comparison of Mastoscopic and Conventional Axillary Lymph Node Dissection in Breast Cancer: Long-Term Results from a Randomized, Multicenter Trial
A group of 1027 consecutive patients with operable breast cancer were randomly assigned to one of two study groups: mastoscopic axillary lymph node dissection and conventional axillary lymph node dissection. The median follow-up was 63 months. The primary end points of the study were operative outcomes, complication reduction, function conservation, and cosmetics. [Mayo Clin Proc] Abstract | Press Release

Learn More: Column-Free Enrichment of Mouse Mammary Stem & Progenitor Cells

Emerging Treatment Options for the Management of Brain Metastases in Patients with HER2-Positive Metastatic Breast Cancer
This review summarizes the known clinical data for the systemic treatment of human epidermal growth factor receptor-2 (HER2)-positive central nervous system metastases and includes information about ongoing clinical trials of novel therapies as well as emerging strategies for early detection and prevention. [Breast Cancer Res Treat] Full Article

Generex Provides Update on Company Initiatives Including the AE37 Breast Cancer Vaccine Program
Antigen Express, Inc., a wholly-owned subsidiary of Generex, is in late phase II clinical development of a novel immunotherapeutic for breast cancer (AE37) that demonstrates promising trends in preventing relapse. The interim results of the large, controlled, randomized, and single blinded trial were the subject of an end of phase II study report written for submission to the FDA with input from the Antigen Express AE37 Breast Cancer Vaccine Scientific Advisory Board of internationally-recognized experts in the field of breast cancer. [Generex Biotechnology Corporation] Press Release

IntelliCell BioSciences Announces FDA Listing for Human Cells, Tissues, and Cellular Based Products
IntelliCell BioSciences, Inc. announced that it has been notified according to the FDA validation registration number 3009842420, that its new facility located at 460 Park Avenue, New York, NY 10022 is now registered to recover, process, package, store, and label human cells and tissue products such as the IntelliCell autologous stromal vascular fraction cellular product. In the registration notification, FDA acknowledged that the IntelliCell process is to be covered under regulations for tissue products. [PR Newswire Association LLC] Press Release


National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)


NEW Society of Surgical Oncology (SSO) 2013 – The 66th Annual SSO Cancer Symposium
March 6-9, 2013
Washington, United States

our events page to see a complete list of events in the mammary cell community.


Quality Control Operations Coordinator (STEMCELL Technologies, Inc.)

Product Quality Scientist (STEMCELL Technologies, Inc.)

Product Manager – Hematopoietic (STEMCELL Technologies, Inc.)

Scientist – Endothelial Cell Research (STEMCELL Technologies, Inc.)

Research Technologist – Cell Separation (STEMCELL Technologies, Inc.)

Scientist or Engineer – hPSC Bioengineer (STEMCELL Technologies, Inc.)

Associate Attending Breast Pathologist (Memorial Sloan-Kettering Cancer Center)

Postdoctoral Position – Tumor Stem Cells (Cancer Institute of New Jersey)

Higher Scientific Officer – Histopathology/Breast Pathology (Institute of Cancer Research)

Laboratory Heads – Developmental Biology and Stem Cell Biology (RIKEN Center for Developmental Biology)

Postdoctoral Fellow – Cancer Genomics (Mayo Clinic Florida)

Research Fellow – Division of Solid Tumor Oncology (Dana-Farber Cancer Institute)

Recruit Top Talent
: Reach more than 55,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Mammary Cell News: Archives | Events | Contact Us